We have located links that may give you full text access.
Comparative protection of small ruminants against Mannheimia haemolytica infection by inactivated bacterin and toxoid vaccines.
Veterinary World 2023 January
BACKGROUND AND AIM: Mannheimia haemolytica causes respiratory infection and mortality in sheep and goats, similar to the effects in cattle, which causes major economic damage. Regular vaccinations alongside good management practices remain the most efficient tools for controlling this disease. Indeed, vaccines against pasteurellosis are available, but results on their efficacy have varied. Therefore, this study aimed to evaluate the efficacy of three vaccines against mannheimiosis in small ruminants.
MATERIALS AND METHODS: We evaluated three vaccines developed from a local field isolate based on the inactivated bacterium, its toxoid, and a mixture of bacterin/toxoid, which we then tested on sheep and goats. Selected criteria that were evaluated were safety, antibody response, and protection through a challenge. Post-vaccination monitoring was carried out by enzyme-linked immunosorbent assay. The evaluation was based on antibody responses to vaccination in sheep and goats for both bacteria and leukotoxin. Protection was assessed by clinical and lesion scores after the challenge of vaccinated goats with a pathogenic strain.
RESULTS: The three tested vaccines were completely safe, did not cause any adverse reactions, and induced significant antibody titers in immunized animals. Following M. haemolytica challenge, unvaccinated goats showed clinical signs with lesions typical of the disease. Meanwhile, the best protection was obtained with the inactivated combined bacterin/toxoid vaccine.
CONCLUSION: This study highlighted the effectiveness of adding a bacterial toxoid in the vaccine as a promising solution for preventing mannheimiosis in small ruminants. Because of the worldwide distribution of M. haemolytica infection, general prophylaxis based on a combined inactivated vaccine could greatly benefit.
MATERIALS AND METHODS: We evaluated three vaccines developed from a local field isolate based on the inactivated bacterium, its toxoid, and a mixture of bacterin/toxoid, which we then tested on sheep and goats. Selected criteria that were evaluated were safety, antibody response, and protection through a challenge. Post-vaccination monitoring was carried out by enzyme-linked immunosorbent assay. The evaluation was based on antibody responses to vaccination in sheep and goats for both bacteria and leukotoxin. Protection was assessed by clinical and lesion scores after the challenge of vaccinated goats with a pathogenic strain.
RESULTS: The three tested vaccines were completely safe, did not cause any adverse reactions, and induced significant antibody titers in immunized animals. Following M. haemolytica challenge, unvaccinated goats showed clinical signs with lesions typical of the disease. Meanwhile, the best protection was obtained with the inactivated combined bacterin/toxoid vaccine.
CONCLUSION: This study highlighted the effectiveness of adding a bacterial toxoid in the vaccine as a promising solution for preventing mannheimiosis in small ruminants. Because of the worldwide distribution of M. haemolytica infection, general prophylaxis based on a combined inactivated vaccine could greatly benefit.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app